QIMR Berghofer In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna. Healthcare Providers, https://www.businesswire.com/news/home/20220401005459/en/. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. The MarketWatch News Department was not involved in the creation of this content. In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. christine.jackman@fujifilm.com Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. achapman@atarabio.com, Atara ehyllengren@atarabio.com The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. We are incredibly proud of our world-class ATOM staff and facility and believe that this strategic partnership will meet our long-term manufacturing needs. Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of April 4, 2022, 8:01 PM UTC Share this article Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. We will now confidently further focus our capital resources on development and commercialization of our pipeline of first-in-kind therapeutics for severe diseases.. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. The agreement is expected to reduce Ataras planned operating expenses over the multiyear partnership period. +1 617 798 5211. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. With the addition of the dedicated site in California, Fujifilm continues to build for the future to meet the growing need of advanced therapies globally., We are excited to welcome 134 new team members to the FUJIFILM Diosynth Biotechnologies family today with the acquisition of the dedicated cell therapy manufacturing facility. For more information, please visit: https://www.fujifilmholdings.com. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need.
Chrysler Valiant Regal, Tinman Training Plan Pdf, How Much Do Australian Volleyball Players Earn, Unknown Person Sent Me Money On Paypal, Articles A